AbbVie Files BPCIA Suit Against Boehringer Ingelheim Over Humira® (Adalimumab)
Two New Applications for Trastuzumab (Herceptin®) Biosimilars Pending at FDA
Sandoz Enters IPR Battlefield on Humira® Patents
Samsung Bioepis and Merck Launch Renflexis® in the U.S.
FDA Grants Tentative Approval for Merck’s Insulin Glargine
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars
Boehringer Ingelheim Prevails in IPR Against AbbVie’s ’135 Humira Patent
Pfizer Challenges Another Herceptin® Patent With Two New IPR Petitions
